Drug intelligence / Profile preview

C12T12

Development stage: Unknown
Lead developer: Cannatrek
Modality: Small Molecules
Administration: Oral

Overview

C12T12 is a medicinal cannabis oil formulation, specifically known as Cannatrek C12T12 Ruby Oil, which contains equal parts of Cannabidiol (CBD) and Tetrahydrocannabinol (THC), typically at a concentration of 12.5mg/ml for each. It is administered orally and is currently being investigated in a pilot study for its potential to ease symptoms in paediatric palliative care. The active cannabinoids, CBD and THC, interact with the body's endocannabinoid system, primarily targeting CB1 and CB2 receptors, to modulate various physiological processes and provide therapeutic effects such as pain relief, anxiety reduction, and improved sleep quality.

Brand names: Cannatrek C12T12 Ruby Oil
Other names: Cannatrek Ruby Balanced Oil12mg/mL CBD + 12mg/mL THC oil

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on C12T12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C12T12.

Explore the full profile